Updated:
Epilog Partners
Epilog Partners runs tech-enabled healthcare buyouts from Boston and Dallas, managing $178 million in pooled vehicles with $50M–$200M equity checks.
Epilog Partners
Epilog Partners operates as a private equity firm focused exclusively on technology-enabled healthcare services, deploying capital from offices in Boston and Dallas. The firm pools investor commitments into discretionary vehicles, with regulatory filings indicating roughly $178 million in regulatory assets under management. Epilog targets leveraged buyouts of profitable healthcare companies in payer services, provider services, and pharma services verticals. It writes equity checks between $50 million and $200 million, aiming to accelerate growth at businesses where enterprise software and AI/ML integration can improve clinical, financial, and experiential outcomes. The firm pursues buyout, growth, and recapitalization structures across North America. Epilog maintains a dual-coast presence with operations in Boston and Dallas. The firm manages pooled investment vehicles structured for institutional and private investors seeking concentrated exposure to healthcare services. Epilog Partners couples a narrow healthcare software thesis with a classic buyout fund structure, distinguishing it from both broad-sector tech investors and pure-play healthcare growth equity managers. By requiring portfolio companies to be cash-flow-positive at entry and investing through a blind-pool vehicle, the firm offers a defined risk profile within an asset class heavy on venture-stage and distressed situations.
General information
Firm type
Private Equity
Year founded
—
AUM
$178M (Altss estimate)
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Additional offices
Dallas, TX, United States
Sector focus
Frequently asked questions
What is Epilog Partners' core investment strategy?
Epilog runs a classic buyout strategy centered on tech-enabled healthcare. The firm targets profitable payer, provider, and pharma services companies where enterprise software and AI can improve outcomes. Equity checks range from $50 million to $200 million, and the firm also pursues growth equity and recapitalization opportunities within the same vertical.
What asset classes or structures does Epilog use?
Epilog deploys capital through pooled private equity vehicles — essentially a blind-pool fund structure. The strategy is pure private equity, with no publicly disclosed debt, real estate, or fund-of-funds programs. The firm does direct control and minority investments, but all sit within the same buyout-oriented pooled vehicles.
How is Epilog different from a venture capital firm in digital health?
Epilog requires cash-flow positivity at entry, making it a buyout shop rather than a venture investor. While many digital health investors write smaller checks into unprofitable growth-stage companies, Epilog targets mature, profitable businesses and writes $50 million-plus checks, applying a private equity control-and-optimization playbook to healthcare services.
Which sectors does Epilog explicitly avoid?
Epilog discloses no activity outside healthcare services and healthcare IT. The firm does not invest in biotech, medtech, payor underwriting, or direct care delivery outside its tech-enabled payer, provider, and pharma services focus. There is no indication of consumer internet, fintech, or industrial exposure.
Does Epilog co-invest alongside external GPs or limited partners?
Epilog has not publicly disclosed a co-investment program. The firm manages pooled vehicles that centralize deal execution, and its regulatory filings do not describe separate managed accounts or SPV-based co-investment offerings alongside the main fund. The current structure suggests a traditional blind-pool LP commitment model.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: